AlloVir Inc (ALVR)
0.9596
+0.07
(+8.18%)
USD |
NASDAQ |
Nov 05, 16:00
0.9596
0.00 (0.00%)
After-Hours: 19:03
AlloVir Enterprise Value: -27.28M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | -27.28M |
| November 01, 2024 | -19.62M |
| October 31, 2024 | -22.32M |
| October 30, 2024 | -27.40M |
| October 29, 2024 | -26.53M |
| October 28, 2024 | -31.06M |
| October 25, 2024 | -36.97M |
| October 24, 2024 | -38.48M |
| October 23, 2024 | -41.70M |
| October 22, 2024 | -39.90M |
| October 21, 2024 | -40.20M |
| October 18, 2024 | -40.42M |
| October 17, 2024 | -40.42M |
| October 16, 2024 | -37.26M |
| October 15, 2024 | -39.36M |
| October 14, 2024 | -31.08M |
| October 11, 2024 | -32.71M |
| October 10, 2024 | -35.89M |
| October 09, 2024 | -36.12M |
| October 08, 2024 | -38.17M |
| October 07, 2024 | -37.33M |
| October 04, 2024 | -38.99M |
| October 03, 2024 | -35.21M |
| October 02, 2024 | -34.44M |
| October 01, 2024 | -35.59M |
| Date | Value |
|---|---|
| September 30, 2024 | -36.34M |
| September 27, 2024 | -37.44M |
| September 26, 2024 | -39.48M |
| September 25, 2024 | -40.78M |
| September 24, 2024 | -41.52M |
| September 23, 2024 | -39.75M |
| September 20, 2024 | -41.30M |
| September 19, 2024 | -38.47M |
| September 18, 2024 | -41.93M |
| September 17, 2024 | -43.09M |
| September 16, 2024 | -41.93M |
| September 13, 2024 | -42.83M |
| September 12, 2024 | -43.20M |
| September 11, 2024 | -42.35M |
| September 10, 2024 | -42.44M |
| September 09, 2024 | -43.85M |
| September 06, 2024 | -41.45M |
| September 05, 2024 | -41.77M |
| September 04, 2024 | -42.62M |
| September 03, 2024 | -41.93M |
| August 30, 2024 | -39.71M |
| August 29, 2024 | -40.26M |
| August 28, 2024 | -41.93M |
| August 27, 2024 | -41.24M |
| August 26, 2024 | -39.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-135.78M
Minimum
Dec 29 2023
2.508B
Maximum
Dec 04 2020
554.95M
Average
277.41M
Median
Enterprise Value Benchmarks
| CEL-SCI Corp | 50.50M |
| AIM ImmunoTech Inc | 8.843M |
| IGC Pharma Inc | 26.81M |
| NovaBay Pharmaceuticals Inc | 3.645M |
| Protalix BioTherapeutics Inc | 69.53M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.076M |
| Total Expenses (Quarterly) | 7.262M |
| EPS Diluted (Quarterly) | -0.05 |
| Earnings Yield | -128.2% |